Over 10 years we help companies reach their financial and branding goals. Engitech is a values-driven technology agency dedicated.

Gallery

Contacts

411 University St, Seattle, USA

+1 -800-456-478-23

News

Myeloid Therapeutics Presents Multiple Posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

-Data underlie the ongoing clinical advance of MT-302, the world’s first in vivo mRNA CAR drug development candidate- -Myeloid also highlights its pioneering CRISPR-Enabled Autonomous Transposable Element (CREATE) platform technology for precision, RNA-mediated gene editing and delivery- CAMBRIDGE, Mass, May 7, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced multiple […]

News

Myeloid Expands Leadership Team with Robert Hofmeister, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass, Feb 1 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Robert Hofmeister, Ph.D., as Chief Scientific Officer (CSO). An expert in immuno-oncology, gene and cell therapy, Dr. Hofmeister brings more than 25 years of scientific leadership experience and a track record of drug discovery and early development. “As […]

News

Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes

CAMBRIDGE, Mass, Jan 5, 2024 – Prime Medicine, Inc. (Nasdaq: PRME) (“Prime Medicine”) and Myeloid Therapeutics, Inc. (“Myeloid”), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a positive outcome for both parties. “I am happy we have reached an amicable settlement with Myeloid. We believe resolving […]

News

Myeloid Announces Appointment of Matthew Maurer, M.D. as Chief Medical Officer

CAMBRIDGE, Mass, December 6, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Matthew Maurer, M.D. as Chief Medical Officer. Dr. Maurer is an experienced physician-scientist with over fifteen years of clinical oncology experience as a drug developer and a principal investigator advancing multiple cancer programs through the early and late […]

News

Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors

MT-302 arms myeloid cells with an mRNA-encoded CAR to kill tumor cells expressing TROP2, and trigger an adaptive immune response to metastatic epithelial tumors CAMBRIDGE, Mass, September 12, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic […]

News

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline

Financing accelerates MT-302, the Company’s first clinical candidate for in vivo cell programming, into a Phase 1/2 clinical trial for TROP2+ solid tumors CAMBRIDGE, Mass., May 18, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from […]

News

Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the AACR

Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the American Association for Cancer Research (AACR) 2023 Annual Meeting CAMBRIDGE, Mass, April 17, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced its presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held in Orlando, […]

News

Myeloid Therapeutics and New South Wales (NSW) Government in Australia Announce Collaboration

Myeloid Therapeutics and New South Wales (NSW) Government in Australia Announce Collaboration to Design, Build, and Launch State-of-the-Art GMP Manufacturing Facility Dedicated to RNA Immunotherapies – NSW will invest AU $96 million to support the facility design, construction and roll-out – – Myeloid will operate the facility and bring its RNA know-how and leadership to […]

News

Myeloid Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day

CAMBRIDGE, Mass, January 26, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that management will present at the Guggenheim Healthcare Talks 2023 Oncology Day, being held February 8-9, 2023, in New York, NY. Daniel Getts, Ph.D., CEO of Myeloid, will present a company overview on Wednesday, February 8, 2023, at […]

News

Myeloid Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass, January 5, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that Daniel Getts, Ph.D., CEO of Myeloid, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023, in San Francisco, CA. The company is scheduled to present on Thursday, January 12, 2023, at […]